Pfizer Inventory 2010-2024 | PFE
Pfizer inventory from 2010 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
- Pfizer inventory for the quarter ending September 30, 2024 was $11.721B, a 14.87% increase year-over-year.
- Pfizer inventory for 2023 was $10.189B, a 13.45% increase from 2022.
- Pfizer inventory for 2022 was $8.981B, a 0.86% decline from 2021.
- Pfizer inventory for 2021 was $9.059B, a 12.96% increase from 2020.
Pfizer Annual Inventory
(Millions of US $) |
| 2023 |
$10,189 |
| 2022 |
$8,981 |
| 2021 |
$9,059 |
| 2020 |
$8,020 |
| 2019 |
$7,068 |
| 2018 |
$7,508 |
| 2017 |
$7,578 |
| 2016 |
$6,783 |
| 2015 |
$7,513 |
| 2014 |
$5,663 |
| 2013 |
$6,166 |
| 2012 |
$6,076 |
| 2011 |
$6,610 |
| 2010 |
$8,275 |
| 2009 |
$12,403 |
Pfizer Quarterly Inventory
(Millions of US $) |
| 2024-09-30 |
$11,721 |
| 2024-06-30 |
$11,447 |
| 2024-03-31 |
$10,892 |
| 2023-12-31 |
$10,189 |
| 2023-09-30 |
$10,204 |
| 2023-06-30 |
$10,310 |
| 2023-03-31 |
$9,541 |
| 2022-12-31 |
$8,981 |
| 2022-09-30 |
$9,513 |
| 2022-06-30 |
$10,454 |
| 2022-03-31 |
$9,979 |
| 2021-12-31 |
$9,059 |
| 2021-09-30 |
$8,640 |
| 2021-06-30 |
$8,948 |
| 2021-03-31 |
$8,493 |
| 2020-12-31 |
$8,020 |
| 2020-09-30 |
$9,295 |
| 2020-06-30 |
$8,564 |
| 2020-03-31 |
$8,423 |
| 2019-12-31 |
$7,068 |
| 2019-09-30 |
$8,222 |
| 2019-06-30 |
$8,233 |
| 2019-03-31 |
$8,029 |
| 2018-12-31 |
$7,508 |
| 2018-09-30 |
$8,184 |
| 2018-06-30 |
$8,074 |
| 2018-03-31 |
$8,148 |
| 2017-12-31 |
$7,578 |
| 2017-09-30 |
$7,925 |
| 2017-06-30 |
$7,584 |
| 2017-03-31 |
$7,415 |
| 2016-12-31 |
$6,783 |
| 2016-09-30 |
$7,507 |
| 2016-06-30 |
$7,614 |
| 2016-03-31 |
$7,578 |
| 2015-12-31 |
$7,513 |
| 2015-09-30 |
$7,678 |
| 2015-06-30 |
$5,796 |
| 2015-03-31 |
$5,786 |
| 2014-12-31 |
$5,663 |
| 2014-09-30 |
$6,355 |
| 2014-06-30 |
$6,249 |
| 2014-03-31 |
$6,066 |
| 2013-12-31 |
$6,166 |
| 2013-09-30 |
$6,482 |
| 2013-06-30 |
$6,282 |
| 2013-03-31 |
$7,035 |
| 2012-12-31 |
$6,076 |
| 2012-09-30 |
$7,516 |
| 2012-06-30 |
$7,001 |
| 2012-03-31 |
$7,189 |
| 2011-12-31 |
$6,610 |
| 2011-09-30 |
$8,426 |
| 2011-06-30 |
$8,597 |
| 2011-03-31 |
$8,467 |
| 2010-12-31 |
$8,275 |
| 2010-09-30 |
$8,771 |
| 2010-06-30 |
$9,511 |
| 2010-03-31 |
$10,132 |
| 2009-12-31 |
$12,403 |
| 2009-09-30 |
$5,058 |
| 2009-06-30 |
$4,993 |
| 2009-03-31 |
$4,458 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
